⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234128 | 0.86 | — | — | |
| SCHEMBL8200634 | 0.86 | RAB9A (0.42) | — | |
| SCHEMBL5367283 | 0.81 | — | — | |
| SCHEMBL10016152 | 0.77 | — | — | |
| SCHEMBL12990402 | 0.77 | PRKDC (0.46) | — | |
| SCHEMBL12215859 | 0.76 | PIK3CD (0.41) | — | |
| SCHEMBL4442166 | 0.74 | ERN1 (0.39) | — | |
| SCHEMBL12025003 | 0.74 | PDPK1 (0.32) | — | |
| SCHEMBL25316693 | 0.73 | — | — | |
| SCHEMBL12917968 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049073-A1 | SPECTACLE LENS COMPRISING AN ORGANIC DYE | OAKLEY, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| US-12532662-B2 | Organic semiconducting compounds | Raynergy Tek Incorporation (TW) | 2026-01-20 | — | — | US | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4573092-A1 | 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | Olema Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-115836054-B | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| WO-2024039860-A1 | 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | OLEMA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | disclosed |
| CN-112352328-B | Organic semiconductor compound | 天光材料科技股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20030096737-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| WO-2002092590-A1 | FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002085899-A1 | HETEROCYCLYLDICARBAMIDES AS CASPASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-31 | — | — | WO | disclosed |
| US-5430059-A | Treating heart disease | EISAI CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| EP-0633248-A1 | Butenoic acid derivatives | Eisai Co., Ltd. (JP) | 1995-01-11 | — | — | EP | disclosed |
| EP-0589491-A1 | Butenoic acid derivatives | Eisai Co., Ltd. (JP) | 1994-03-30 | — | — | EP | disclosed |
| US-5292770-A | Butenoic acid derivatives | EISAI CO., LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| US-5166188-A | Cardiovascular disorders, antiischemic agents | EISAI CO., LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| US-4996227-A | Administering nontoxic antitumor agents | UNIVERSITY OF CINCINNATI (US) | 1991-02-26 | — | — | US | disclosed |
| EP-0399358-A2 | Butenoic acid derivatives | Eisai Co., Ltd. (JP) | 1990-11-28 | — | — | EP | disclosed |